BioLineRx Accounts Payable from 2010 to 2024

BLRX Stock  USD 0.47  0  0.21%   
BioLineRx Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable is likely to outpace its year average in 2024. Accounts Payable is the amount BioLineRx owes to suppliers or vendors for products or services received but not yet paid for. It represents BioLineRx's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2009-12-31
Previous Quarter
8.3 M
Current Value
6.3 M
Quarterly Volatility
2.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 2.3 M or Selling General Administrative of 17.5 M, as well as many indicators such as Price To Sales Ratio of 19.85, Dividend Yield of 0.0 or PTB Ratio of 8.01. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
  
Check out the analysis of BioLineRx Correlation against competitors.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Latest BioLineRx's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of BioLineRx over the last few years. An accounting item on the balance sheet that represents BioLineRx obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of BioLineRx are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. BioLineRx's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

BioLineRx Accounts Payable Regression Statistics

Arithmetic Mean4,997,975
Geometric Mean4,132,082
Coefficient Of Variation63.39
Mean Deviation2,540,883
Median4,493,000
Standard Deviation3,168,170
Sample Variance10T
Range9.8M
R-Value0.87
Mean Square Error2.6T
R-Squared0.76
Significance0.000022
Slope618,119
Total Sum of Squares140.5T

BioLineRx Accounts Payable History

202411.4 M
202310.9 M
2022M
20215.6 M
20205.9 M
20197.8 M
20184.5 M

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable10.9 M11.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.